SCHEMBL1446949

SCHEMBL1446949

CCOC(=O)c1c(-c2cc(O)c(O)c([N+](=O)[O-])c2)coc1-c1ccc(C)[n+]([O-])c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
COMT P21964 2/20 0.40
MAPT P10636 4/20 0.38
ALOX5 P09917 4/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
ALDH1A1 P00352 2/20 0.34
ABCC3 O15438 1/20 0.34
ABCC4 O15439 1/20 0.34
NR1I2 O75469 1/20 0.34
ABCB11 O95342 1/20 0.34
TTR P02766 1/20 0.34
NR3C1 P04150 1/20 0.34
PGR P06401 1/20 0.34
HTR1A P08908 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
RARB P10826 1/20 0.34
SLC6A2 P23975 1/20 0.34
ADORA1 P30542 1/20 0.34
ADRA1A P35348 1/20 0.34
PTGS2 P35354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1447092 0.90 MAPT (0.38) COMTMAPTALOX5MEN1KMT2A
SCHEMBL1447027 0.87 COMT (0.42) COMTMAPTALOX5MEN1KMT2A
SCHEMBL3592544 0.83 MAPT (0.39) COMTMAPTALOX5MEN1KMT2A
SCHEMBL1446980 0.82 MAPT (0.39) COMTMAPTALOX5MEN1KMT2A
SCHEMBL1447411 0.82 MAPT (0.37) COMTMAPTALOX5MEN1KMT2A
SCHEMBL1447471 0.82 COMT (0.49) COMTMAPTALOX5MEN1KMT2A
SCHEMBL1448322 0.81 MAPT (0.40) COMTMAPTALOX5MEN1KMT2A
SCHEMBL1447322 0.81 MAPT (0.38) COMTMAPTALOX5MEN1KMT2A
SCHEMBL3591295 0.80 MAPT (0.39) COMTMAPTALOX5MEN1KMT2A
SCHEMBL3586259 0.80 MAPT (0.40) COMTMAPTALOX5TTRAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220388999-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL PORTELA & CA SA (PT) 2022-12-08 US disclosed
US-20200102295-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL - PORTELA & CA, S.A. (PT) 2020-04-02 US disclosed
US-10336740-B2 Nitrocatechol derivatives as COMT inhibitors BIAL—PORTELA & CA, S.A. (PT) 2019-07-02 US disclosed
US-20170362213-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS PORTELA & COMPANHIA, S.A. (PT) 2017-12-21 US disclosed
US-9550759-B2 Nitrocatechol derivatives as COMT inhibitors BIAL—PORTELA & CA, S.A. (PT) 2017-01-24 US disclosed
EP-1907382-B1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL PORTELA & CA SA (PT) 2015-05-27 EP disclosed
US-20150072977-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL - PORTELA & CA, S.A. (PT) 2015-03-12 US disclosed
US-8907099-B2 Nitrocatechol derivatives as COMT inhibitors BIAL-PORTELA & CA, S.A. (PT) 2014-12-09 US disclosed
US-20120196904-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS PORTELA & CA., S.A. (PT) 2012-08-02 US disclosed
US-8168793-B2 Nitrocatechol derivatives as COMT inhibitors PORTELA & CA., S.A. (PT) 2012-05-01 US disclosed
EP-2301934-A1 Nitrocatechol derivatives as COMT inhibitors BIAL - Portela & Ca., S.A. (PT) 2011-03-30 EP disclosed
US-20090054437-A1 Nitrocatechol Derivatives as Comt Inhibitors PORTELA & CA., S.A. (PT) 2009-02-26 US disclosed
EP-1907382-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS Portela & C.A. S.A (PT) 2008-04-09 EP disclosed
WO-2007013830-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS PORTELA & CA. S.A. (PT) 2007-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362213-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885MAPT 694/4885ALOX5 1612/4885
US-20150072977-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885MAPT 694/4885ALOX5 1612/4885
US-20220388999-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885MAPT 664/4885ALOX5 1588/4885
US-20090054437-A1 Nitrocatechol Derivatives as Comt Inhibitors COMT, PNMT, OPRK1 COMT 1/4885MAPT 694/4885ALOX5 1612/4885
US-10336740-B2 Nitrocatechol derivatives as COMT inhibitors COMT, PNMT, OPRK1 COMT 1/4885MAPT 694/4885ALOX5 1612/4885
US-20200102295-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885MAPT 664/4885ALOX5 1588/4885
US-20120196904-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 COMT 1/4885MAPT 694/4885ALOX5 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.